The kisspeptin-GnRH pathway in human reproductive health and disease

por Skorupskaite, Karolina, George, Jyothis T, Anderson, Richard A
Publicado 2014

Neurokinin B Regulates Gonadotropin Secretion, Ovarian Follicle Growth, and the Timing of Ovulation in Healthy Women

por Skorupskaite, Karolina, George, Jyothis T., Veldhuis, Johannes D., Anderson, Richard A.
Publicado 2017

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® t...

por Sattar, Naveed, Fitchett, David, Hantel, Stefan, George, Jyothis T., Zinman, Bernard
Publicado 2018

Bladder cancer in the EMPA-REG OUTCOME trial

por Kohler, Sven, Lee, Jisoo, George, Jyothis T., Inzucchi, Silvio E., Zinman, Bernard
Publicado 2017

Atrial fibrillation associated with a thyroid stimulating hormone-secreting adenoma of the pituitary gland leading to a presentation of acute cardiac decompensation: A case report

por George, Jyothis T, Thow, Jonathan C, Matthews, Bruce, Pye, Maurice P, Jayagopal, Vijay
Publicado 2008

Non-European Union doctors in the National Health Service: why, when and how do they come to the United Kingdom of Great Britain and Northern Ireland?

por George, Jyothis T, Rozario, Kavitha S, Anthony, Jeffrin, Jude, Edward B, McKay, Gerard A
Publicado 2007

Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women

por Skorupskaite, Karolina, George, Jyothis T., Veldhuis, Johannes D., Millar, Robert P., Anderson, Richard A.
Publicado 2016

Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome

por Skorupskaite, Karolina, George, Jyothis T, Veldhuis, Johannes D, Millar, Robert P, Anderson, Richard A
Publicado 2020

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

por Ceriello, Antonio, Ofstad, Anne Pernille, Zwiener, Isabella, Kaspers, Stefan, George, Jyothis, Nicolucci, Antonio
Publicado 2020

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG...

por Verma, Subodh, Mazer, C. David, Fitchett, David, Inzucchi, Silvio E., Pfarr, Egon, George, Jyothis T., Zinman, Bernard
Publicado 2018

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits

por McGuire, Darren K., Inzucchi, Silvio E., Johansen, Odd Erik, Rosenstock, Julio, George, Jyothis T., Marx, Nikolaus
Publicado 2021

Training tomorrow's doctors in diabetes: self-reported confidence levels, practice and perceived training needs of post-graduate trainee doctors in the UK. A multi-centre survey

por George, Jyothis T, Warriner, David A, Anthony, Jeffrin, Rozario, Kavitha S, Xavier, Sinu, Jude, Edward B, McKay, Gerard A
Publicado 2008

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial

por Fitchett, David, Inzucchi, Silvio E, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Vedin, Ola, Zinman, Bernard, Johansen, Odd Erik
Publicado 2020

MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D

por Inzucchi, Silvio E, Davies, Melanie, Khunti, Kamlesh, Trivedi, Prabhav, George, Jyothis T, Zwiener, Isabella, Johansen, Odd Erik, Sattar, Naveed
Publicado 2020

Brief Intervention in Type 1 diabetes – Education for Self-efficacy (BITES): Protocol for a randomised control trial to assess biophysical and psychological effectiveness

por George, Jyothis T, Valdovinos, Abel Peña, Thow, Jonathan C, Russell, Ian, Dromgoole, Paul, Lomax, Sarah, Torgerson, David J, Wells, Tony
Publicado 2007

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial

por Inzucchi, Silvio E, Khunti, Kamlesh, Fitchett, David H, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Ofstad, Anne Pernille, Zinman, Bernard
Publicado 2020

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes

por Inzucchi, Silvio E., Davies, Melanie J., Khunti, Kamlesh, Trivedi, Prabhav, George, Jyothis T., Zwiener, Isabella, Johansen, Odd Erik, Sattar, Naveed
Publicado 2020

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial

por Shimada, Akira, Hanafusa, Toshiaki, Yasui, Atsutaka, Lee, Ganghyuck, Taneda, Yusuke, Sarashina, Akiko, Shiki, Kosuke, George, Jyothis, Soleymanlou, Nima, Marquard, Jan
Publicado 2018

Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placeb...

por Kawamori, Ryuzo, Haneda, Masakazu, Suzaki, Keiko, Cheng, Gang, Shiki, Kosuke, Miyamoto, Yuki, Solimando, Fernando, Lee, Christopher, Lee, Jisoo, George, Jyothis
Publicado 2018

Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, place...

por Kaku, Kohei, Haneda, Masakazu, Tanaka, Yuko, Lee, Ganghyuck, Shiki, Kosuke, Miyamoto, Yuki, Solimando, Fernando, Lee, Jisoo, Lee, Christopher, George, Jyothis
Publicado 2018